Related Experiment Video
Updated: May 8, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Variability of bioavailability and intestinal absorption mechanisms of metoprolol
Miki Fukao1, Kazuya Ishida, Asuka Horie
1Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama.
Abstract:
We previously reported that aging and/or cytochrome P450 2D6 polymorphism are responsible for the interindividual variability in the systemic clearance (CL) and bioavailability (F) of metoprolol. The aim of the present study was to evaluate the residual variability of F of metoprolol in routinely treated Japanese patients and to investigate the intestinal absorption mechanism of the drug using human intestinal epithelial LS180 cells. We first re-analyzed the blood concentration data for metoprolol in 34 Japanese patients using a nonlinear mixed effects model. The oral clearance (CL/F) of metoprolol was positively correlated with the apparent volume of distribution (V/F), suggesting the residual variability of F. The uptake of metoprolol into LS180 cells was significantly decreased by the acidification of extracellular medium pH, and was dependent on temperature and intracellular pH. Furthermore, the cellular uptake of metoprolol was saturable, and was significantly decreased in the presence of hydrophobic cationic drugs such as diphenhydramine, procainamide, bisoprolol, and quinidine. These findings indicate that residual variability of F is one of the causes of the interindividual pharmacokinetic variability of metoprolol, and that the interindividual variability of not only presystemic first-pass metabolism, but also intestinal absorption, may be responsible for the variable F of the drug.
Insights
Residual variability in metoprolol bioavailability (F) contributes to pharmacokinetic differences among patients. Intestinal absorption mechanisms, influenced by pH and drug interactions, also play a role in this variability.
Area of Science:
- Pharmacokinetics
- Drug Metabolism and Transport
- Gastroenterology
Background:
- Interindividual variability in metoprolol pharmacokinetics is partly explained by aging and CYP2D6 genotype.
- Residual variability in bioavailability (F) requires further investigation.
Purpose of the Study:
- To evaluate residual variability of metoprolol bioavailability (F) in Japanese patients.
- To investigate the intestinal absorption mechanism of metoprolol.
Main Methods:
- Re-analysis of metoprolol blood concentration data using nonlinear mixed effects modeling.
- In vitro studies using LS180 human intestinal epithelial cells to assess metoprolol uptake.
Main Results:
- Oral clearance (CL/F) correlated positively with apparent volume of distribution (V/F), indicating residual variability in F.
- Metoprolol uptake into LS180 cells was pH-dependent, temperature-sensitive, and saturable.
- Uptake was inhibited by hydrophobic cationic drugs, suggesting transporter involvement.
Conclusions:
- Residual variability in metoprolol bioavailability (F) contributes to interindividual pharmacokinetic variability.
- Variability in intestinal absorption, alongside first-pass metabolism, influences metoprolol's variable bioavailability.
Related Concept Videos
Bioavailability: Influencing Factors
Bioavailability: Overview
Bioavailability: Overview
Factors Influencing Bioavailability: First-Pass Elimination
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Factors Influencing Drug Absorption: Presystemic Elimination
